YDES YD Bio (YDES) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-medical laboratories · CIK 0002011674
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · no price filed
What the filings say about YDES
Insiders, 180 days
+$128.5K net bought
1 buyer
YD Bio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, YD Bio Ltd insiders bought a net $128.5K of stock across 3 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 9, 2026.
- The trade is 0.1% of the 11,258,331 shares held after it.
- No other insider bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Shen Ethan PhD bought about $48.9K of YDES on Sep 14, 2026; 10 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 4, 2026.
- The trade is 0.0% of the 11,245,631 shares held after it.
- No other insider bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Shen Ethan PhD bought about $12.2K of YDES on Sep 9, 2026; 10 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.2% of the 11,242,531 shares held after it.
- No other insider bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Shen Ethan PhD bought about $67.4K of YDES on Sep 4, 2026, the largest insider purchase at the company on our record; 10 funds added in the latest 13F quarter.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$128.5K over 180 days
+$128.5K over 90 days
more than 79% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 94% of Healthcare Services
Revenue
+16.9% year over year
more than 63% of Healthcare Services
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 79% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch YDES
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-65.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns YDES: institutional holders (13F)
13F holdings, latest reported quarter
4,678,142 sh
$1.5M
100,000 sh
$225.0K
84,630 sh
$190.4K
352,495 sh
$172.1K
62,714 sh
$141.1K
Congress trades in YDES
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
YDES planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $128.5K bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
YDES financials
Revenue growth
+16.9%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$421.6M
market value at close 2026-10-27 on 2025-12-31 shares, plus long-term debt only, 2025-12-31, minus cash 2025-12-31
Enterprise value YDES
| FY Dec 2025 | $856.9M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing YDES
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | |
|---|---|---|---|
| Revenue | $596.8K | $510.4K | $350.1K |
| Gross profit | $167.4K | $155.4K | $153.4K |
| Operating income | -$5.3M | -$1.5M | -$9.8K |
| Net income | -$8.3M | -$1.4M | $13.6K |
| EPS (diluted) | -0.12 | -0.02 | 0.00 |
| Operating cash flow | -$6.6M | -$1.2M | -$55.7K |
| Cash | $6.0M | $3.1M | n/a |
| Long-term debt | $6.8K | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
YDES Stock Sonar score 4/7 axes
Find similar shapesCompareYDES ranks highest on risk and compliance (74th percentile) and insider conviction (71st), and lowest on institutional and government (6th), among Healthcare Services peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
YDES filings, in plain words
Are YD Bio insiders buying or selling YDES?
In the 180 days to 2026-10-28, YD Bio insiders were net buyers, a net $128.5K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, YD Bio insiders were net buyers of YDES, a net $128.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
